Latest news with #UtkarshaSoundankar
Cision Canada
10-07-2025
- Business
- Cision Canada
Dräger Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care training SAN ANTONIO, July 10, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Dräger has received the 2025 Global Company of the Year Award in the respiratory devices industry for its outstanding achievements in clinical innovation, cost-effective solutions, customer-centric strategy execution, and global market impact. This recognition underscores Dräger's continued leadership in transforming respiratory care through advanced technologies, comprehensive training programs, and a deep-rooted commitment to improving patient outcomes and caregiver wellness in intensive care environments. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: visionary innovation and customer impact. Dräger excelled in both, demonstrating its ability to align its innovation roadmap with market demand while executing with precision, scalability, and clinical relevance. "Keeping the customer need in mind, Dräger's designs focus on a range of consumer needs, including scalability, flexibility, low infection rates, low readmission rates, reduced costs, high return on investment for healthcare providers, workplace safety, process improvement, human error reduction, enhanced patient and family experiences, patient comfort, and operational efficiencies," said Utkarsha Soundankar, Industry Analyst at Frost & Sullivan. Guided by a long-term growth strategy focused on digital innovation, clinical partnerships, and value-based care, Dräger has demonstrated its ability to lead in a rapidly evolving respiratory care landscape. The company's sustained investment in smart ventilator technology, workflow integration, and clinician training has enabled it to scale its solutions across diverse healthcare systems globally. Innovation remains at the heart of Dräger's approach. Its V-Series ventilators—featuring SmartCare/PS, integrated capnography, proportional pressure support, and high-flow oxygen therapy—are purpose-built to support the improvement of clinical outcomes, reduce the duration of mechanical ventilation, and support bundled payment models. Dräger's recent achievement in securing Authority to Operate (ATO) certification for its Evita V800/V600, Babylog VN800, and Savina 300 ventilators from the US Department of Defense marks a significant milestone in medical device security, interoperability, and deployment in mission-critical environments. "Given the recent wave of market consolidation of vendors in the ventilation market, today's decision makers are seeking more than just high-quality devices—they're looking for trusted partners who are deeply committed to supporting the respiratory care community," said Lothar Thielen, President and CEO of Draeger, Inc. "This award is a powerful affirmation of Dräger's unwavering commitment to our customers to deliver exceptional value through a combination of industry-leading products, cost-effective accessories and comprehensive service solutions that help hospitals provide the highest standard of care." In addition to product innovation, Dräger is redefining the respiratory care ecosystem through its full-service offerings, including responsive maintenance programs, biomedical training, and digital education platforms. In 2024, the company introduced Dräger Virtuo, an immersive virtual reality platform for ICU, OR, and NICU training, unveiled at the American Association for Respiratory Care (AARC) Congress. Alongside this launch, the revitalized Dräger Academy continues to expand its impact by delivering more than 84,500 hours of CRCE credits annually and offering micro-learning modules tailored for clinicians' evolving needs. This integrated education model is designed to build clinical confidence and ensure rapid onboarding and knowledge retention—imperative in high-stakes care environments. Frost & Sullivan commends Dräger for setting the benchmark in strategic execution and customer-focused innovation in the respiratory devices industry. The company's holistic approach—combining clinical-grade technology, secure deployment, and professional development—continues to support redefining the standard for excellence in respiratory care. Its ability to aid in improving clinical workflows, lowering total cost of care, and expanding access to next-generation training aims to ensure lasting impact across global healthcare ecosystems. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: E: [email protected] Dräger. Technology for Life Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in Lübeck, Germany in 1889, Dräger generated global sales of around EUR 3 billion in 2022. The Lübeck-based company is represented in more than 190 countries and employs more than 14,000 people worldwide. For more information, visit
Yahoo
10-06-2025
- Business
- Yahoo
Ambiq Receives Frost & Sullivan's 2025 Global Company of the Year Award for Its Leadership in Healthcare Semiconductor Solutions
Ambiq recognized for pioneering energy-efficient semiconductor solutions that empower next-generation AI-enabled healthcare innovations SAN ANTONIO, June 10, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Ambiq has been awarded the 2025 Global Company of the Year Award in the semiconductor solutions for the healthcare industry for its outstanding achievements in innovation, technology advancement, and customer-centric strategy execution. This recognition highlights Ambiq's unwavering leadership in developing ultra-low power semiconductor platforms that are transforming digital health solutions and enabling AI-powered diagnostics and monitoring at the edge. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Ambiq excelled in both areas, demonstrating its ability to anticipate evolving market needs while consistently delivering cutting-edge products that enhance performance, energy efficiency, and scalability across healthcare and related sectors. "Ambiq's primary focus lies on delivering energy-efficient solutions with extended battery life. The company is also implementing solutions or models for AI that can enable the expansion of ultra-low power edge AI technologies," said Utkarsha Soundankar, industry analyst at Frost & Sullivan. Guided by a forward-looking growth strategy that prioritizes research and development, ecosystem collaboration, and application-specific innovation, Ambiq has successfully positioned itself at the forefront of the semiconductor market. The company's strategic agility and sustained investment in edge AI and low-power computing have enabled it to scale its technology globally while delivering targeted solutions that meet the demands of modern digital healthcare systems. Innovation is at the heart of Ambiq's operational ethos. Its Apollo System-on-Chip (SoC) series, now in its fifth generation, is setting new standards for energy efficiency in smart health devices. The Apollo510 combines an Arm Cortex-M55 CPU with Helium technology, advanced security features like secureSPOT and Arm TrustZone with PUF, and dynamic graphics performance via its 2.5D GPU. The company plans to release variations of both current and next-gen Apollo SoCs to cater to customers of all sizes and their power needs for AI-enabled devices. "We are honored to be awarded the prestigious Frost & Sullivan award in Healthcare Semiconductor Solutions," says Fumihide Esaka, CEO of Ambiq. "Since our founding, we have been on a mission to enable intelligence everywhere, a mission that often aligns with our digital health customer's mission of making healthcare more accessible to everyone. We're proud to help these healthcare innovators meet this mission in making effective patient care more efficient, available, and less costly using our ultra-low power semiconductors and solutions." In addition to its Apollo series, Ambiq's suite of technologies—powered by its patented Subthreshold Power Optimized Technology (SPOT®) platform—includes the Artasie real-time clocks for power optimization, the neuralSPOT AI development kit, and heartKIT®, which enables accurate AI-driven ECG monitoring. These innovations collectively extend device battery life while supporting always-on, intelligent applications across wearables, diagnostic tools, and connected medical devices. Ambiq's unwavering commitment to customer success further strengthens its position as a partner of choice in the healthcare semiconductor space. By maintaining close collaboration with device manufacturers and solution providers, Ambiq accelerates time-to-market for new products and ensures that partners receive the technical and operational support needed for long-term success. Its partnerships with companies like CardioMedive, Smartaly, and Bravechip underscore its ability to deliver reliable, high-performance, and energy-efficient chipsets that address real-world challenges in cardiovascular monitoring, wearable diagnostics, and IoT integration. Frost & Sullivan commends Ambiq for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, robust innovation pipeline, and customer-first culture are shaping the future of semiconductor technologies for healthcare and unlocking new possibilities for edge AI and intelligent diagnostics worldwide. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. To learn more about why Ambiq was chosen as Frost & Sullivan's Company of the Year for Healthcare Semiconductor Solutions, read the complete evaluation report here. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact:Ashley ShreveE: About Ambiq Our mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. We enable our customers to deliver artificial intelligence compute at the edge where power consumption challenges are the most profound. Our technology innovations, built on the patented and proprietary subthreshold power optimized technology (SPOT), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. We've powered over 270 million devices today. For more information, visit Contact Charlene WanVP of Marketing and Investor Relationscwan@ View original content: SOURCE Frost & Sullivan View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
10-06-2025
- Business
- Cision Canada
Ambiq Receives Frost & Sullivan's 2025 Global Company of the Year Award for Its Leadership in Healthcare Semiconductor Solutions
Ambiq recognized for pioneering energy-efficient semiconductor solutions that empower next-generation AI-enabled healthcare innovations SAN ANTONIO, June 10, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Ambiq has been awarded the 2025 Global Company of the Year Award in the semiconductor solutions for the healthcare industry for its outstanding achievements in innovation, technology advancement, and customer-centric strategy execution. This recognition highlights Ambiq's unwavering leadership in developing ultra-low power semiconductor platforms that are transforming digital health solutions and enabling AI-powered diagnostics and monitoring at the edge. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Ambiq excelled in both areas, demonstrating its ability to anticipate evolving market needs while consistently delivering cutting-edge products that enhance performance, energy efficiency, and scalability across healthcare and related sectors. "Ambiq's primary focus lies on delivering energy-efficient solutions with extended battery life. The company is also implementing solutions or models for AI that can enable the expansion of ultra-low power edge AI technologies," said Utkarsha Soundankar, industry analyst at Frost & Sullivan. Guided by a forward-looking growth strategy that prioritizes research and development, ecosystem collaboration, and application-specific innovation, Ambiq has successfully positioned itself at the forefront of the semiconductor market. The company's strategic agility and sustained investment in edge AI and low-power computing have enabled it to scale its technology globally while delivering targeted solutions that meet the demands of modern digital healthcare systems. Innovation is at the heart of Ambiq's operational ethos. Its Apollo System-on-Chip (SoC) series, now in its fifth generation, is setting new standards for energy efficiency in smart health devices. The Apollo510 combines an Arm Cortex-M55 CPU with Helium technology, advanced security features like secureSPOT and Arm TrustZone with PUF, and dynamic graphics performance via its 2.5D GPU. The company plans to release variations of both current and next-gen Apollo SoCs to cater to customers of all sizes and their power needs for AI-enabled devices. "We are honored to be awarded the prestigious Frost & Sullivan award in Healthcare Semiconductor Solutions," says Fumihide Esaka, CEO of Ambiq. "Since our founding, we have been on a mission to enable intelligence everywhere, a mission that often aligns with our digital health customer's mission of making healthcare more accessible to everyone. We're proud to help these healthcare innovators meet this mission in making effective patient care more efficient, available, and less costly using our ultra-low power semiconductors and solutions." In addition to its Apollo series, Ambiq's suite of technologies—powered by its patented Subthreshold Power Optimized Technology (SPOT®) platform—includes the Artasie real-time clocks for power optimization, the neuralSPOT AI development kit, and heartKIT®, which enables accurate AI-driven ECG monitoring. These innovations collectively extend device battery life while supporting always-on, intelligent applications across wearables, diagnostic tools, and connected medical devices. Ambiq's unwavering commitment to customer success further strengthens its position as a partner of choice in the healthcare semiconductor space. By maintaining close collaboration with device manufacturers and solution providers, Ambiq accelerates time-to-market for new products and ensures that partners receive the technical and operational support needed for long-term success. Its partnerships with companies like CardioMedive, Smartaly, and Bravechip underscore its ability to deliver reliable, high-performance, and energy-efficient chipsets that address real-world challenges in cardiovascular monitoring, wearable diagnostics, and IoT integration. Frost & Sullivan commends Ambiq for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, robust innovation pipeline, and customer-first culture are shaping the future of semiconductor technologies for healthcare and unlocking new possibilities for edge AI and intelligent diagnostics worldwide. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. To learn more about why Ambiq was chosen as Frost & Sullivan's Company of the Year for Healthcare Semiconductor Solutions, read the complete evaluation report here. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: E: [email protected] About Ambiq Our mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. We enable our customers to deliver artificial intelligence compute at the edge where power consumption challenges are the most profound. Our technology innovations, built on the patented and proprietary subthreshold power optimized technology (SPOT), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. We've powered over 270 million devices today. For more information, visit Contact Charlene Wan VP of Marketing and Investor Relations [email protected] +1.512.879.2850 SOURCE Frost & Sullivan
